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Background. Engagement of individuals infected with hepatitis C virus (HCV) with care pathways remains a major barrier to
realizing the beneﬁts of new and more effective antiviral therapies. After an exploratory study, we have undertaken an evidence-based
redesign of care pathways for HCV, including the following: (1) reﬂex testing of anti-HCV-positive samples for HCV RNA; (2) an-
notation of laboratory results to recommend referral of actively infected patients to specialist clinics; (3) educational programs for
primary care physicians and nurses; and (4) the establishment of needs-driven community clinics in substance misuse services.
Methods. In this study, we conducted a retrospective cohort study of progression through care pathways of individuals with a
new diagnosis of HCV infection made between January 2010 and January 2012. We also analyzed patient ﬂow through new care
pathways and compared this with our baseline study of identical design.
Results. A total of 28 980 samples were tested for anti-HCV antibody during the study period and yielded 273 unique patients
with a new diagnosis of HCV infection. Of these, 38% were tested in general practice, 21% were tested in substance misuse services,
23% were tested in secondary care, and 18% were tested in local prisons. Overall, 80% of patients were referred to specialist clinics,
70% attended for assessment, and 38% commenced treatment, in comparison to 49%, 27%, and 10%, respectively, in the baseline
study. Referral rates from all testing sources improved.
Conclusions. This study provides timely evidence that progression through care pathways can be enhanced, and it demonstrates
reduction of key barriers to eradication of HCV.
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It is estimated that between 130 and 170 million individuals
worldwide are chronically infected with hepatitis C virus, repre-
senting 2%–3% of the world population [1]. Hepatitis C virus
(HCV) is estimated to cause more than 350 000 deaths per
annum, and up to 27% of cases of cirrhosis of the liver and
25% of hepatocellular carcinomas (HCCs) worldwide are attrib-
utable to HCV [2]. In most developed countries, including those
in Western Europe and North America, the burden of HCV is
<2%, and transmission is strongly associated with injecting drug
use [1, 3–6]. In England, approximately 215 000 individuals are
living with HCV [7], and half of all those who inject drugs are
infected [8]. Hospital admissions and deaths from HCV-related
end-stage liver disease and HCC in the United Kingdom have
risen year-on-year and will continue to do so exponentially
until the burden of HCV infection is reduced [7].
The recent introduction of directly acting antiviral agents has
demonstrated the potential to transform outcomes for individ-
uals infected with HCV [9–13]. New treatment schedules are
typically less toxic, more effective, and of shorter duration
than previous interferon-based therapies [9–13] and have raised
the possibility of eradicating HCV in populations where re-
sources are not constrained. However, these improvements in
the efﬁcacy and tolerability of antiviral therapies have also
brought into sharp focus the major challenges of accessing the
HCV-infected population. Public Health England has estimated
that between 2006 and 2012, only 3% of chronically infected pa-
tients in the United Kingdom were treated each year [7], and low
rates of engagement and treatment of HCV-infected populations
are widely reported in other developed countries [14–17].
In order to realize the vision of eradication of HCV infection,
it will be mandatory to increase both the rates of diagnosis of
HCV infection and the subsequent engagement of infected in-
dividuals with treatment pathways. We have previously evaluat-
ed outcomes for patients newly diagnosed as HCV antibody
positive in a representative healthcare region in England during
the period from November 2000 to October 2002. This study
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found that of the 256 individuals newly identiﬁed as infected
with HCV during the study period, <30% attended specialist
clinics only 26 (<10%) received treatment [18]. We accordingly
introduced a comprehensive set of changes to local care path-
ways, and we report the results of a follow-up study interrogat-
ing outcomes for a cohort of patients from the same health
region recently diagnosed with active HCV infection.
METHODS
Identiﬁcation of Patient Cohort and Data Collection
The starting point for this retrospective cohort study was a data-
base of all serum samples tested for anti-HCVantibody andHCV
RNA in the Microbiology Laboratory of the Nottingham Univer-
sity Hospitals NHS Trust (NUH) between January 2010 and Jan-
uary 2011. The Nottingham laboratory serves 2 large general
hospitals, together with primary (community) care and specialist
services in the city, conurbation and surrounding rural area, with
a combined population of approximately 750 000. From this da-
tabase, all samples with an anti-HCV-positive test result were ex-
tracted and ﬁltered for unique records to identify the number of
individuals with a positive anti-HCV result. For each anti-HCV-
positive patient, pre-existing laboratory databases were searched
for evidence of a previous diagnosis of HCV infection, and any
patient previously found to have been infected was excluded. Pa-
tients were then assigned to 4 groups on the basis of the source of
their diagnostic tests: general practice, substance misuse services,
secondary care, and prisons. The study cohort was observed for
an additional 12 months until January 2013 to ensure that all
those with a new diagnosis of HCV had been given the opportu-
nity to engage with specialist services. The only treatment avail-
able to our cohort throughout the study period was pegylated
interferon and ribavirin. Therefore, our study results were not
confounded by the availability of new antiviral regimens.
After our baseline study, we initiated 4 interventions de-
signed to enhance engagement with the care pathway. These in-
terventions were not introduced at the same time, because each
needed to be developed and implemented separately. The
changes made to our care pathway for HCV were as follows.
(1) Reﬂex testing of any anti-HCV-positive sample for HCV
RNA became standard practice within the NUH microbiology
laboratory. This new practice unequivocally identiﬁed actively
infected patients and eliminated the need to arrange repeat
blood tests on all antibody-positive patients (introduced in
2008). (2) If the HCV-RNA test was positive, a note was
added to the laboratory report requesting that the testing agency
refer the patient to a hepatitis clinic, thus removing the need for
primary care physicians to interpret the laboratory results and
clearly setting out a recommended course of action (introduced
in 2008). (3) An educational program was introduced regarding
blood-borne viruses, comprising seminars and discussion
groups delivered to local primary care physicians (general prac-
titioners; GPs) and practice nurses, with the aim of improving
their understanding of the natural history of HCV and its diag-
nosis and management (introduced in 2007). One us (B.J.T.)
was then instrumental in establishing a national training re-
source for GPs, hosted by the UK Royal College of General
Practitioners [19], and for ensuring high local uptake of this
program. (4) We eased the local treatment selection criteria,
which had previously excluded all patients who were active sub-
stance misusers, and established nurse-led treatment clinics in
Nottingham’s principal statutory drug treatment clinic in the
city center, and in a large inner city primary care health center
delivering shared care for intravenous drug users [20].
To assess outcomes, the hospital electronic patient informa-
tion system was searched for evidence of referral to a hepatitis
specialist services and subsequent assessment and treatment.
We next interrogated the agency performing the diagnostic
test if the patient was not referred to a specialist assessment.
For GPs, this was done via a postal questionnaire; for drug ser-
vices, contact was made by telephone, and the electronic patient
information system was used to follow up outcomes of those di-
agnoses made in secondary care. For diagnoses made in large
prisons, the electronic patient information system was searched
for explanations for lack of referral. For several patients diag-
nosed at smaller prisons, who lacked evidence of referral for
treatment, we sent follow-up questionnaires to the prison’s
healthcare department.
RESULTS
Of 28 980 samples tested for anti-HCV during the 2-year study
period, 1083 were found to be positive. Of these samples, 1025
were patient identiﬁable and linked to 742 unique patients, 377
of whom met the criteria for a new diagnosis. Of these patients,
348 (94%) had an associated RNA HCV-RNA test result, and
237 of these patients were HCV-RNA positive and were adopt-
ed as the study cohort. The characteristics and source of referral
for the study cohort are shown in Table 1.
Table 1. Patient Characteristics
Gender
General
Practice
Substance
Misuse Services
Secondary
Care Prisons Total
Male 58 36 32 43 169
Female 32 14 22 0 68
Age range (years)
<15 2% 0 2% 0 1%
15–24 12% 3% 2% 9% 8%
25–34 27% 50% 33% 40% 36%
35–44 29% 30% 26% 44% 31%
45–54 19% 12% 22% 7% 16%
55+ 11% 2% 15% 0 8%
Past injecting drug use
Yes 43% 88% 46% 60% 57%
No 33% 0 24% 5% 19%
Unknown 24% 12% 30% 35% 24%
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Of the 237 patients identiﬁed as newly diagnosed with active
HCV infection, 90 (38%) had been tested within general prac-
tice. Fifty (21%) patients were diagnosed in substance misuse
services. These include the city’s principal drug treatment
service, a specialist needle exchange, and an inpatient detox-
iﬁcation facility. We also note that 23 of the 90 patients
assigned to general practice were diagnosed at practices oper-
ating “shared care” drug treatment clinics in association with
a local substance misuse service. Fifty-four (23%) patients
were diagnosed in a diverse range of specialties in second-
ary (hospital) care, including gastroenterology, hepatology,
genitourinary medicine, antenatal clinics, and the admission
wards. Forty-three (18%) patients were diagnosed in 3 local
prisons.
Relationship Between the Source of the Positive Test and Progress
Along Care Pathway
A summary of the progress along the care pathway for each of
the 4 patient groups is shown in Table 2, with the following
commentary.
General Practice
By the end of the study, of the 90 patients diagnosed in general
practice, there was evidence to indicate that 83 (92%) had been
referred for assessment at a hepatitis clinic. In 3 cases, the pa-
tients had been referred for treatment in a neighboring city. Of
the 7 patients who were not referred, the GP sent feedback in 6
cases. One patient had not returned for their results, 4 had been
given their results but had since left the practice, and 1 had de-
clined the offer of referral. There was evidence that 74 of the 83
referred patients (89%) attended the specialist clinic.
Substance Misuse Services
Of the 50 patients diagnosed in substance misuse services, 42
(84%) had been referred to a specialist for treatment in a hepatitis
clinic. Thirty-six of these patients were seen in one of the com-
munity hepatitis clinics recently established in Nottingham. Of
the 8 patients for whom no evidence of referral could be found,
4 had been diagnosed at the inpatient detoxiﬁcation facility,
which routinely informs the drug treatment provider of results
rather than refer directly. Only 3 patients had been assessed as
too chaotic to refer by their substance misuse service. There
was evidence that 35 (83%) of the referred patients attended an
assessment with a hepatitis specialist, and the majority of these
patients attended specialist HCV services within community
clinics. Thirty-four of these assessments took place in specialist
HCV services placed within community clinics.
Secondary Care
Of the 54 patients diagnosed by secondary care, 41 (76%) were
subsequently referred for assessment by a specialist. Although it
was difﬁcult to determine reasons for nonreferrals, we found
that 2 patients died shortly after diagnosis, 1 from HCC and 1
due to human immunodeﬁciency virus-related illness. We also
found that 2 patients were from outside the Nottingham area
and a third had left the area since diagnosis. One patient tested
in the emergency department had no known GP. Thirty-eight
patients (93%) attended initial assessment.
Prisons
Forty-three people were diagnosed after testing in the 3 local
prisons. Of these, there is evidence that 24 (56%) were referred
for assessment. Of the 19 patients who may not have been re-
ferred, 10 had been moved to another prison or released shortly
after diagnosis, 2 had spontaneously cleared the virus, and 1 had
not been referred due to mental health issues. Reasons for non-
referral of the remaining 6 prisoners could not be determined.
Eighteen of the 24 patients (75%) had attended an assessment in
a hepatitis clinic, and we found that the 6 who did not attend
were either released or moved after referral. The attrition
along the care pathway is shown for all clients in Figure 1.
DISCUSSION
The principle ﬁndings of this study are the striking improve-
ment in engagement with care pathways as assessed by rates
of referral to specialist care and attendance for assessment, to-
gether with commencement of treatment, for patients with
newly diagnosed HCV infection. These results are in contrast
to our previous identical study [18].
Overall, 80% of the patients were referred to a hepatitis spe-
cialist, 70% attended assessment, and 38% commenced treat-
ment, compared with 49%, 27%, and 10%, respectively, in the
earlier study (Table 3). Patients diagnosed in primary care re-
main the most likely to be referred to specialist care, with
Table 2. Progress of Patients Diagnosed With Active Hepatitis C Virus (HCV) Infection Along the Care Pathwaya
Source of
Diagnosis
No. of Patients Diagnosed
With Active HCV Infection
No. of Patients Referred to
Specialist Care (%)
No. of Patients Attended
Assessment (%)
No. of Patients Commencing
Antiviral Treatment (%)
General Practice 90 83 (92) 74 (82) 41 (46)
Substance Misuse 50 42 (84) 35 (70) 18 (36)
Secondary Care 54 41 (76) 38 (70) 21 (39)
Prisons 43 24 (56) 18 (42) 11 (25)
Total 237 190 (80) 165 (70) 91 (38)
a Figures at each point are expressed as absolute numbers and as percentage of the total number of patients diagnosed for each source.
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92% of patients referred, compared with 66% of patients in the
earlier study. Referral rates for patients diagnosed in substance
misuse services have also improved dramatically, with 84% of
patients being referred, compared with 42% of patients in the
earlier study. Taking into account the 23 patients who were di-
agnosed in shared care clinics in general practice, the percentage
of patients identiﬁed as HCV positive in substance misuse ser-
vices and referred to specialist clinics rises to 88%, with the ma-
jority attending for assessment. Attendance at the community-
based clinics among patients with a history of injecting drugs
was particularly excellent. The proportion of patients diagnosed
in secondary care, who were then referred for assessment, in-
creased from 55% to 76%. Although the prisons showed the
highest increase in the referral rate, from 18% of patients to
56%, they remain the setting in which referral to specialist
care is least likely to occur.
United Kingdom national policies were initiated during the
study period and may have contributed to increased engage-
ment observed in our study. The Hepatitis C Strategy and Ac-
tion Plan for England in 2004 [21, 22] set out to increase public
Figure 1. A summary of progress of the patient cohort along the care pathway with the reasons for loss of patients at each point identified.
Table 3. Comparison of Outcomes With Earlier Study
Study Cohort
No. of Patients
in Cohort
No. of Patients Referred to
Specialist Care (%)
No. of Patients Who
Attended Assessment (%)
No. of Patients Commenced
on Treatment (%)
2010–2011 cohort 237 190 (80) 165 (70) 91 (38)
2000–2002 cohort 256 125 (49) 68 (27) 26 (10)
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and professional awareness of HCV and provide an operational
framework for more effective intervention, and there is some
evidence to support a positive effect of these policies on rates
of testing. The proportion of the participants in the UK Health
Protection Authority’sUnlinked Anonymous Monitoring Survey
of People Who Inject Drugs who reported having ever been test-
ed for hepatitis C rose from 54% in 2001 to 83% in 2011 [8].
Overall, however, the introduction of national guidelines has
not led to major sustained improvement in rates of HCV testing
over the study period, and there is no evidence of widespread
increases in engagement with HCV pathways [23].
The availability of new and less toxic treatments for HCV will
unquestionably increase the proportion of individuals seen in
clinic who will progress to antiviral treatment. Better available
treatments may also increase levels of engagement with care path-
ways. However, fear of side effects is only one factor in a complex
and interlinked set of barriers to engagement with treatment ser-
vices among people who currently or previously injected drugs.
These include the following: a lack of knowledge and understand-
ing about HCV and its consequences; competing priorities with
current drug use, housing, health, or ﬁnances; stigma associated
with HCV and injecting drug use; the asymptomatic nature of
HCV infection; and fear of medical investigations, together
with concerns over the efﬁcacy and side effects of treatment
[24–31]. The barriers to engagement with testing and treatment
for HCV in disadvantaged populations are located in society,
rather than solely pharmacological [17, 32], and continue to be
perceived as a major challenge to reducing the burden of HCV
disease in the United Kingdom [23]. Our solution included the
creation of facilities designed to meet the needs of our vulnerable
populations, such as the delivery of antiviral therapy as part of
drug treatment programs [20], but it included simple measures
to engage with healthcare professionals that also led to increased
attendance at our hospital-based clinics.
CONCLUSIONS
This is the ﬁrst study to provide unequivocal evidence that en-
gagement with care pathways for patients with HCV infection in
England can be improved. These improvements are likely to be a
direct result of an intervention set designed to integrate and en-
hance the continuum of HCV care. The patient group studied
and the medical facilities in which the diagnosis and referral
occur are highly heterogeneous and a particularly challenging
area for research. It is likely that the efﬁcacy of any single inter-
vention will differ between patient groups, and therefore we de-
signed this study to determine the impact of the interventions as
a composite set of public health measures. Our work also identi-
ﬁes points where loss of patients from the care pathway continues
to occur and provides an analysis of the reasons for this attrition
(Figure 1). We note that improvements in the outcomes of the
care pathway after a number of interventions, including the pro-
vision of outreach clinics in drug services and prison settings,
have been reported in Scottish Specialist HCV setting [33]. It is
also interesting to note that an analysis of the care continuum in a
major US urban center [16] found results remarkably similar to
those of our previous study in 2006 [18].The study by Viner et al
[16] found that of those individuals with a new diagnosis of HCV
infection, 46% were subsequently conﬁrmed to be RNA positive,
13% entered care pathways, and only 7% received treatment. This
contemporary study conﬁrms that patient engagement is a pre-
requisite for realizing the beneﬁts of new directly acting antiviral
therapies, and it emphasizes the importance of our central mes-
sage that targeted public health measures can increase engage-
ment of the HCV-infected population with care pathways.
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